Patents by Inventor Avi Ben-Shimon

Avi Ben-Shimon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide compounds and therapeutic uses of same
    Patent number: 11912790
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 27, 2024
    Assignee: Immunity Pharma Ltd.
    Inventors: Eran Ovadia, Avi Ben-Shimon
  • PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME
    Publication number: 20230049549
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.
    Type: Application
    Filed: January 14, 2021
    Publication date: February 16, 2023
    Applicant: Immunity Pharma Ltd.
    Inventors: Eran OVADIA, Avi BEN-SHIMON, Ilana COHEN
  • PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISRODERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53
    Publication number: 20220251159
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Application
    Filed: December 13, 2021
    Publication date: August 11, 2022
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD
    Inventors: Varda ROTTER, Moshe OREN, Perry TAL, Shay EIZENBERGER, Avi BEN-SHIMON
  • Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53
    Patent number: 11230578
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 25, 2022
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Varda Rotter, Moshe Oren, Perry Tal, Shay Eizenberger, Avi Ben-Shimon
  • PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME
    Publication number: 20210261615
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
    Type: Application
    Filed: July 10, 2019
    Publication date: August 26, 2021
    Applicant: Immunity Pharma Ltd.
    Inventors: Eran OVADIA, Avi BEN-SHIMON
  • PEPTIDES AND USE OF SAME IN THE TREATMENT OF DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH A MUTANT P53
    Publication number: 20190048053
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 14, 2019
    Inventors: Varda ROTTER, Moshe OREN, Perry TAL, Shay EIZENBERGER, Avi BEN-SHIMON
  • Identification of active sites in enzymes
    Publication number: 20060188870
    Abstract: A method for determining the location of the active site of an enzyme is provided. The method comprising: determining a location of a reference point inside a functional unit of the enzyme; determining a limiting distance from the reference point; and identifying one or more molecular surface portions within the limiting distance to determine whether the molecular surface portion is part of the active site.
    Type: Application
    Filed: February 23, 2006
    Publication date: August 24, 2006
    Inventors: Avi Ben-Shimon, Miriam Eisenstein